Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sab Biotherapeutics Inc (NQ: SABS )

0.9600 +0.0100 (+1.05%)
Streaming Delayed Price Updated: 3:59 PM EDT, Jun 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 90,640
Open 0.9500
Bid (Size) 0.9202 (5)
Ask (Size) 0.9494 (1)
Prev. Close 0.9500
Today's Range 0.9200 - 0.9798
52wk Range 0.3657 - 1.930
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
SAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International Convention
SAB Biotherapeutics President & Chief Executive Officer Eddie Sullivan, Ph.D. to present novel DiversitAb™ platform pipeline, with emphasis on partnering influenza therapeutic, SAB-176 
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Presents Virtual 2023 R&D Day Portfolio Update: Breakthrough Immunotherapy Innovations
From SAB Biotherapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+47.69%
+47.69%
1 Month
-2.04%
-2.04%
3 Month
+60.16%
+60.16%
6 Month
-2.27%
-2.27%
1 Year
-46.67%
-46.67%

More News

Read More
SAB Biotherapeutics: Q1 Earnings Insights
Via Benzinga
SAB Biotherapeutics Provides Company Update for Q1 2023 Financial Results
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Announces First Publication of Promising Nonclinical Data for SAB-183 Against Pneumonic Plague in the Journal Antibodies
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Announces Progress on U.S. FDA’s Phased Review of Company’s Groundbreaking DiversitAb™ Platform
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
SAB Biotherapeutics Presents Positive Phase 1 and 2a Data for SAB-176 Influenza Immunotherapy at ISIRV-AVG Conference
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
EXCLUSIVE: SAB Biotherapeutics' Influenza Immunotherapy Shows Safety, Efficacy In Early-Stage Trials
Via Benzinga
SAB Biotherapeutics to Present at Sidoti Virtual Investor Conference, May 10-11
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Announces Positive Results from Phase 3 Trial of SAB-185 in Patients with COVID-19 at High-Risk for Severe Complications
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
EXCLUSIVE: SAB Biotherapeutics Releases Topline Data From Discontinued COVID Antibody Trial
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Travelers Companies Shares Are Trading Higher By Over 5%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Why Sonnet BioTherapeutics Shares Are Trading Lower By Around 13%; Here Are 20 Stocks Moving Premarket
Via Benzinga
SAB Biotherapeutics Gets FDA Breakthrough Therapy Status On Influenza Treatment Candidate, Analysts Maintain Bullish Pitch
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Glory Star New Media Group Shares Are Trading Higher By 122%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Dow Dips Over 100 Points; Bank of America Earnings Beat Estimates
Via Benzinga
Short Volatility Alert: Sab Biotherapeutics
Via Benzinga
SAB Biotherapeutics Announces U.S. FDA Grants Breakthrough Therapy Designation to SAB-176 Influenza Immunotherapy
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
EXCLUSIVE: SAB Biotherapeutics Secures FDA Breakthrough Therapy Tag For Its Influenza Immunotherapy
Via Benzinga
Promising Upsides on these Biotech Penny Stocks
Via MarketBeat
Why Teva Pharmaceutical Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.